Last reviewed · How we verify
Formulation B: OnabotulinumtoxinA
At a glance
| Generic name | Formulation B: OnabotulinumtoxinA |
|---|---|
| Also known as | BOTOX |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles (PHASE4)
- A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formulation B: OnabotulinumtoxinA CI brief — competitive landscape report
- Formulation B: OnabotulinumtoxinA updates RSS · CI watch RSS
- Allergan portfolio CI